News on microarrays, multiplexing, genotyping, cytogenetics, gene expression profiling in genetics, genomics, and molecular diagnostics.
The company's total revenues were $23.1 million, supported by growth across the firm's instrument and consumables sales, and its research collaboration business.
The test is designed to identify a tumor's tissue of origin by assessing 2,000 individual genes and covers 15 common tumor types.
The exclusive two-way licensing deal also allows Akonni to commercialize Righton's molecular diagnostic tests outside of China.
The company aims to shore up its core nCounter platform business with new consumables, as it continues to work on new technologies and explore clinical translation.
The company's total revenues were $35.2 million during the quarter compared to $25.2 million during the same period in 2016. Full-year results also beat analyst estimates.